Video Panel: How China Inc. Sells Latest Therapies In An Untapped Market
Top Execs Discuss If Country Can Become True Global Player
During the “Road to Commercialization” panel session during EBD/Informa Connect's recent annual ChinaBio partnering event, senior executives from top Chinese biotechs along with a leading contract manufacturing organization and venture fund shared views on biologics commercialization in China. Partnerships to accelerate the process, as well as the future commercial direction of novel biologics in their fastest-growing market worldwide, were also discussed.
You may also be interested in...
Just three years after its founding, Chinese cell therapy developer IASO Bio already has two assets in clinical development and the Nanjing firm has recently attracted $60m in financing. In an exclusive interview, its R&D head told Scrip that speed and partnerships are propelling Chinese developers on a trajectory to quickly catch up with the west in the emerging cell-therapy arena.
In a bid widely seen as a move to double down on their “in China for China” strategy, Sanofi and Roche have formed new drug development alliances with local innovative players potentially worth billions.
From BeiGene to Innovent to Wuxi Biologics, executives at Chinese pharma firms are now discussing collaborations to go beyond China to become biopharma operations with a truly global presence.